VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO WCGIC 2020 | PANGEA: personalized antibodies for gastroesophageal adenocarcinoma

Daniel Catenacci, MD, of the University of Chicago, Chicago, IL, discusses the phase IIa PANGEA study (NCT02213289), a precision medicine trial in gastroesophageal adenocarcinoma, evaluating biomarkers for antibody therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter